CRYBG2 and ovarian cancer: Previously, AIM1L mRNA overexpression was identified in several cancer cell lines including prostate cancer, bladder inverted papilloma, bladder cancer, colon cancer, pancreas cancer, ovarian cancer, endometrial cancer, and breast cancer.